Thuja Capital
- Company typePrivate
- Founded2005
- HeadquartersUtrecht, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Thuja Capital does
Thuja Capital Management BV is a privately-held, Netherlands-based venture capital firm founded in 2005 by Harrold van Barlingen, headquartered in Leiden. The firm specializes in early-stage life sciences investments across the Netherlands, Belgium, and Germany, backing companies developing novel therapeutics, medical devices (including digital health), and nutraceuticals, frequently at the academic spin-off or preclinical proof-of-concept stage. Thuja operates multiple specialized vehicles: TCHF I, II, III, and IV (Thuja Capital Healthcare Funds), and Magnolia MedTech Fund I, with TCHF III closing at EUR 76M (USD 86M) in December 2021 and a portfolio spanning more than 30 companies. Its investor base (limited partners) includes the European Investment Fund, ASR, Dutch and Walloon regional investment agencies, and a consortium of Dutch and Belgian university knowledge institutions such as Sanquin, Utrecht University, UMC Utrecht, Radboud UMC, KU Leuven, and Delft Enterprises.
The firm monetizes through standard venture capital economics: recurring management fees on committed capital from institutional LPs, supplemented by performance-based carried interest on portfolio exits. It does not sell software, products, or services; rather, it deploys capital into portfolio companies, takes board or observer roles, and provides hands-on support leveraging sector expertise and an academic-clinical-industry network. Notable value-creation milestones include Argenx (USD 700M raise and FDA approval of Vyvgart), MILabs (acquired by Rigaku), and EsoBiotec (acquired by AstraZeneca).
As of 2026, Thuja operates with approximately ten professionals under Managing Partner Michel Briejer and partners including Evan Castiglia (ex-Philips Ventures), following the January 2025 passing of founder Harrold van Barlingen. The firm is a member of Dutch venture associations and is supported by EIF, which signals institutional credibility. Its go-to-market is relationship-driven and selective, anchored by annual events (CEO Day, Portfolio Day), a proprietary impact/ESG reporting framework, and a website-plus-LinkedIn presence, rather than broad marketing campaigns.
Thuja Capital firmographics
Firmographics- Name
- Thuja Capital
- Legal name
- Thuja Capital Management BV
- Website
- https://thujacapital.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Thuja Capital industry classification
Industry- Product category
- Venture Capital / Healthcare Investment Management
- NAICS
- Other Investment Pools and Funds (5259), Portfolio Management and Investment Advice (523940)
- akta.pro primary industry
- Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)
Keywords
Where Thuja Capital is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Thuja Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Management fees: VC fund management fees charged on committed capital from institutional investors including EIF, ASR, Dutch and Walloon regional investment agencies, and universities.
- Carried interest: Performance-based carried interest from successful portfolio company exits, with Argenx being cited as the biggest success from Fund I.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Thuja Capital product offering
Product offeringCore offering
Thuja Capital is an early-stage venture capital firm that manages healthcare-focused investment funds (TCHF I-IV and Magnolia MedTech Fund I) providing equity capital, active management support, board participation, and network access to life sciences companies developing novel therapeutics, medical devices, digital health products, and nutraceuticals in the Netherlands, Belgium, and Germany. Capital is sourced from institutional limited partners including the European Investment Fund, ASR, regional investment agencies, and universities.
Product overview
Thuja Capital is a venture capital firm that manages multiple investment funds (TCHF I, TCHF II, TCHF III, TCHF IV, and Magnolia MedTech Fund I) dedicated to investing in innovative life science companies in Europe. The firm focuses on early-stage investments in biotech and medtech companies, with a portfolio spanning therapeutics, medical devices, and digital health across the Netherlands, Belgium, and Germany.
Differentiator
Problem solved
Functional benefit
Brands
- Thuja Capital Healthcare Fund I (TCHF I): First venture capital fund focused on life sciences investments
- Thuja Capital Healthcare Fund II (TCHF II)
- Thuja Capital Healthcare Fund III (TCHF III)
- Thuja Capital Healthcare Fund IV (TCHF IV)
- Magnolia MedTech Fund I
Products and services
- Thuja Capital Healthcare Fund I (TCHF I) Thuja's first venture capital fund focused on early-stage life sciences investments; made investments in 10 companies including argenx, Thuja's biggest success.
- Thuja Capital Healthcare Fund II (TCHF II) Second venture capital fund by Thuja Capital investing in early-stage life sciences companies.
- Thuja Capital Healthcare Fund III (TCHF III) Third fund focused on early-stage companies developing novel therapeutics, medical devices (including digital health), or nutraceuticals in the Netherlands, Belgium, or Germany, targeting 10-12 portfolio investments. Final close at EUR 76M (USD 86m) in December 2021.
- Thuja Capital Healthcare Fund IV (TCHF IV) Fourth venture capital fund by Thuja Capital for early-stage life sciences investments, referenced in SFDR disclosures.
- Magnolia MedTech Fund I MedTech-focused investment fund investing in young medical technology companies addressing unmet medical needs.
Quantifiable outcome
- Argenx achieved $700M raise and FDA approval of Vyvgart
- +2 more outcomes
Companies that use Thuja Capital
Customer profileSegments2 records
Ideal customer profiles2 records
Thuja Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Thuja Capital partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Sanquinnovatecore5-year collaboration agreement between Sanquinnovate (Sanquin's technology valorization and business development arm) and Thuja Capital. Jointly evaluate projects and business plans regarding novel therapeutics and diagnostics. The aim is to progress excellent scientific projects into start-up companies. Alveron Pharma was co-founded in 2019 through prior collaboration between the parties.
Scale indicators4 records
Recent moves8 records
Expansion highlights5 records
Thuja Capital competitors and assessment
Company assessmentDirect peers
- Forbion: Forbion is one of Europe's largest dedicated life sciences venture capital firms, investing across stages in therapeutics and medtech from offices in the Netherlands and Germany. It is a direct peer to Thuja given overlapping focus on European early-stage biotech and shared Dutch institutional roots.
- EQT Life Sciences (formerly LSP): EQT Life Sciences is a pan-European healthcare investor operating from the Netherlands with multi-stage life sciences funds. It directly competes with Thuja for Dutch and Belgian biotech and medtech deals and overlaps on LP base through EIF and other institutional investors.
- BioGeneration Ventures (BGV): BGV is a Dutch venture capital firm focused on early-stage life sciences companies in the Netherlands, Belgium, and Germany. It directly competes with Thuja Capital in seed and Series A biotech investing across the same Benelux/DACH geography.
- Gilde Healthcare: Gilde Healthcare is a specialized European healthcare investor managing both venture and growth funds focused on therapeutics, medtech, and digital health. It is a direct peer to Thuja with overlapping geographies, fund focus, and target stages.
- Andera Partners: Andera Partners is a Paris-based private equity firm with dedicated life sciences venture and growth activities. It is a direct peer to Thuja given its focus on European biotech and medtech investing and competition for high-quality academic spin-out deals across the continent.
- Sunstone Capital: Sunstone Capital is a Copenhagen-based venture firm with a dedicated Life Sciences fund investing in European early-stage biotech and medtech. It directly competes with Thuja for pan-European seed and Series A opportunities and shares comparable fund sizes.
- Inkef Capital: Inkef Capital is a Dutch venture capital firm with a dedicated life sciences strategy investing in early-stage European therapeutics and medical technology. It is a direct peer to Thuja with overlapping geography, stage focus, and LP base including Dutch institutional investors.
- Seventure Partners: Seventure Partners is a Paris-based VC/PE firm managing life sciences-focused funds across Europe. It is a direct peer to Thuja given its early-stage biotech focus, comparable fund sizes, and competition for European academic spin-out transactions.
- Bracco Ventures / Panakes Partners: Panakes Partners is an Italian venture capital firm investing in early-stage life sciences companies across Europe. It is a direct peer to Thuja in fund size, stage focus, and target geography (though primarily Italy-anchored).
Regional players
- Innovationsfonden (Novo Seeds): Novo Seeds is the early-stage venture arm of Novo Holdings, focused on Danish and Nordic life sciences companies. It is a regional peer to Thuja — comparable in stage focus and life sciences vertical, but anchored in the Nordics rather than Benelux/DACH.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Thuja Capital social profiles
Digital presenceThuja Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Thuja Capital leadership team
Management profileNumber of profiles
Profiles7 records
Thuja Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Thuja Capital M&A and investment
M&A and investmentM&A
Investments62 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Thuja Capital
What does Thuja Capital do?
Thuja Capital is an early-stage venture capital firm that manages healthcare-focused investment funds (TCHF I-IV and Magnolia MedTech Fund I) providing equity capital, active management support, board participation, and network access to life sciences companies developing novel therapeutics, medical devices, digital health products, and nutraceuticals in the Netherlands, Belgium, and Germany. Capital is sourced from institutional limited partners including the European Investment Fund, ASR, regional investment agencies, and universities.
Is Thuja Capital a public or private company?
Thuja Capital is a private company. It is classified as management employee owned and is currently operating.
When was Thuja Capital founded?
Thuja Capital was founded in 2005. It employs 1 to 10 people.
Where is Thuja Capital based?
Thuja Capital is headquartered in Utrecht, Netherlands, in the Europe region.
How does Thuja Capital make money?
Two revenue lines are on record. Management fees are the primary driver. The others are carried interest.
Who are Thuja Capital's main competitors?
Direct peers on record are Forbion, EQT Life Sciences (formerly LSP), BioGeneration Ventures (BGV), Gilde Healthcare, Andera Partners, Sunstone Capital, Inkef Capital, Seventure Partners and Bracco Ventures / Panakes Partners. Innovationsfonden (Novo Seeds) is listed as a regional player.
Does Thuja Capital have an API?
No public API is recorded for Thuja Capital.
What industry is Thuja Capital in?
Thuja Capital's product category is Venture Capital / Healthcare Investment Management. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 5259.